Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2002 1
2003 2
2004 2
2005 1
2006 16
2007 25
2008 24
2009 25
2010 21
2011 29
2012 19
2013 32
2014 14
2015 3
2016 3
2017 3
2018 2
2019 4
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
Nilotinib.
Ostendorf BN, le Coutre P, Kim TD, Quintás-Cardama A. Ostendorf BN, et al. Among authors: quintas cardama a. Recent Results Cancer Res. 2014;201:67-80. doi: 10.1007/978-3-642-54490-3_3. Recent Results Cancer Res. 2014. PMID: 24756785 Review.
Nilotinib.
Quintás-Cardama A, Kim TD, Cataldo V, le Coutre P. Quintás-Cardama A, et al. Recent Results Cancer Res. 2010;184:103-17. doi: 10.1007/978-3-642-01222-8_8. Recent Results Cancer Res. 2010. PMID: 20072834 Review.
GPRC5D-Targeted CAR T Cells for Myeloma.
Quintás-Cardama A. Quintás-Cardama A. N Engl J Med. 2022 Dec 15;387(24):2295-2296. doi: 10.1056/NEJMc2213985. N Engl J Med. 2022. PMID: 36516097 No abstract available.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Quintás-Cardama A, et al. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. Blood. 2010. PMID: 20130243 Free PMC article.
What CAR Will Win the CD19 Race?
Quintás-Cardama A. Quintás-Cardama A. Mol Cancer Ther. 2019 Mar;18(3):498-506. doi: 10.1158/1535-7163.MCT-18-1070. Mol Cancer Ther. 2019. PMID: 30824581 Review.
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.
Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, Zikaras K, Smalley M, Ross M, Tanyi JL, Ghafoor A, Shah NN, Saboury B, Cao L, Quintás-Cardama A, Hong D. Hassan R, et al. Among authors: quintas cardama a. Nat Med. 2023 Aug;29(8):2099-2109. doi: 10.1038/s41591-023-02452-y. Epub 2023 Jul 27. Nat Med. 2023. PMID: 37501016 Free PMC article. Clinical Trial.
Synthetic T cell receptor-based lymphocytes for cancer therapy.
Getts D, Hofmeister R, Quintás-Cardama A. Getts D, et al. Among authors: quintas cardama a. Adv Drug Deliv Rev. 2019 Feb 15;141:47-54. doi: 10.1016/j.addr.2019.04.002. Epub 2019 Apr 12. Adv Drug Deliv Rev. 2019. PMID: 30981835 Review.
Closing in on the pathogenesis of the 5q- syndrome.
Post SM, Quintás-Cardama A. Post SM, et al. Among authors: quintas cardama a. Expert Rev Anticancer Ther. 2010 May;10(5):655-8. doi: 10.1586/era.10.44. Expert Rev Anticancer Ther. 2010. PMID: 20469997 Review.
Tumorigenesis promotes Mdm4-S overexpression.
Pant V, Larsson CA, Aryal N, Xiong S, You MJ, Quintas-Cardama A, Lozano G. Pant V, et al. Among authors: quintas cardama a. Oncotarget. 2017 Apr 18;8(16):25837-25847. doi: 10.18632/oncotarget.15552. Oncotarget. 2017. PMID: 28460439 Free PMC article.
207 results